The U.S. Food and Drug Administration (FDA) announced on Monday the approval of the first generic version of a ...

In a new study, researchers examined the health effects people experienced when they returned to still-standing homes after ...

Novo Nordisk NVO announced disappointing data from a phase III study on a novel obesity candidate. The FDA approved Eli Lilly ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 501.82% and ...

Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk 's ( NVO 0.15%) stock crashed ...

CEO's use of Eli Lilly's (LLY) weight loss drug Mounjaro over Novo Nordisk's (NVO) rival product, Ozempic. Read more here.

The US Food and Drug Administration has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea (OSA).

Global pharma giant Eli Lilly plans to launch its diabetes and obesity treatment, tirzepatide, marketed under the brands Mounjaro and Zepbound, in India by 2025. The proposed dosages ranged from 2.5 ...

The FDA first approved Zepbound to treat obesity in November 2023. Its active ingredient, tirzepatide, was previously ...

The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA).

The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as ...

The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...